IMCD

Lubrizol Engages IMCD Group to Expand Additives Business in South Asia

Retrieved on: 
Wednesday, November 1, 2023
Science, Other Energy, Other Science, Oil, Gas, Other Manufacturing, Energy, Chemicals, Plastics, Manufacturing, Lubricant, IMCD, Urbanization, Multimedia, Speciality chemicals, Renewable energy, Film industry, Lubrizol

Lubrizol believes the finished lubricant market in Bangladesh is expected to grow at a CAGR of 3–5%.

Key Points: 
  • Lubrizol believes the finished lubricant market in Bangladesh is expected to grow at a CAGR of 3–5%.
  • “We see tremendous growth potential in South Asia, and that’s why we are investing in the region and committing to fully supporting oil marketers in Bangladesh,” said Flavio Kliger, senior vice president and president, Lubrizol Additives.
  • “Bangladesh is an evolving marketplace and requires our dedicated support,” said Sanjeev Kaul, vice president, India, Middle East and Africa, Lubrizol Additives.
  • “Together with IMCD, we are fully equipped to provide that support to a growing customer base.”
    Lubrizol has previously worked with IMCD to distribute additives in global markets.

Harrington Process Solutions, a Leading Specialty Distributor of Flow Control Process Solutions, to be Acquired by Bain Capital Private Equity

Retrieved on: 
Thursday, September 7, 2023
Construction & Property, Building Systems, Specialty, Machine Tools, Metalworking & Metallurgy, Supply Chain Management, Other Construction & Property, Manufacturing, Retail, BMO Capital Markets, Semiconductor, LLP, Food, IMCD, Kirkland & Ellis, Körber Process Solutions, Bain Capital, Goldman Sachs, McDermott Will & Emery, Ground substance, PwC, Partner, Investment, Nautic Partners, Water, Filtration, Growth, Private credit, Security (finance), Brenntag

Harrington Process Solutions (“Harrington”, or the “Company”), a leading specialty distributor of industrial flow control process solutions, today announced that it has entered into a definitive agreement to be acquired by Bain Capital Private Equity (“Bain Capital”).

Key Points: 
  • Harrington Process Solutions (“Harrington”, or the “Company”), a leading specialty distributor of industrial flow control process solutions, today announced that it has entered into a definitive agreement to be acquired by Bain Capital Private Equity (“Bain Capital”).
  • Harrington will continue to operate as a standalone company and be led by its current management team.
  • Founded in 1959 and headquartered in Chino, California, Harrington is a leading distributor of piping and other engineered fluid process products for corrosive and high-purity applications.
  • PricewaterhouseCoopers LLP is serving as accounting advisor, and Kirkland & Ellis LLP is serving as legal counsel to Bain Capital.

Engine Capital Announces Its Intent to Support PrimeStone’s Director Candidates at Brenntag’s Upcoming Annual Meeting

Retrieved on: 
Wednesday, May 24, 2023
Professional Services, Finance, Interview, IMCD, Share repurchase, Supervisory board, XETRA, EBITA, Acquisition, Investment, Citigroup, Specialty, Annual general meeting, Capital, Supervision, Growth, Letter, Horizon, Essential, Management, Fine chemical, Brenntag, Univar Solutions

Today, Engine issued an open letter to Brenntag's shareholders announcing its intent to support the two director candidates proposed by shareholder PrimeStone Capital LLP (“PrimeStone”) – Joanna Dziubak and Geoff Wild – at the Company’s upcoming Annual General Meeting (the “Annual Meeting”) scheduled to be held on June 15, 2023.

Key Points: 
  • Today, Engine issued an open letter to Brenntag's shareholders announcing its intent to support the two director candidates proposed by shareholder PrimeStone Capital LLP (“PrimeStone”) – Joanna Dziubak and Geoff Wild – at the Company’s upcoming Annual General Meeting (the “Annual Meeting”) scheduled to be held on June 15, 2023.
  • Importantly, our letter encouraged the Supervisory Board to establish a meaningful share repurchase program and add shareholder representatives to the boardroom.
  • By keeping the division inside Brenntag, Brenntag Specialties is not perceived by customers, suppliers, employees or potential acquisition candidates as a pure-play specialties business.
  • As a first step, we look forward to supporting PrimeStone’s director candidates – Joanna Dziubak and Geoff Wild – at the upcoming Annual Meeting.

Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism

Retrieved on: 
Thursday, April 13, 2023
Data management, IMCD, Biotechnology, Ferroptosis, H. Lee Moffitt Cancer Center & Research Institute, Research, Pharmaceutical industry, Hillstream loach

HSB-1216, Hillstream’s most advanced candidate, utilizes ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death (IMCD) of drug-resistant cancers.

Key Points: 
  • HSB-1216, Hillstream’s most advanced candidate, utilizes ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death (IMCD) of drug-resistant cancers.
  • As part of the agreement, OncoBay Clinical’s engagement will provide comprehensive clinical expertise across data management, statistical programming, scientific writing, regulatory affairs and clinical operations services for clinical, and observational studies.
  • Additionally, OncoBay will leverage the support of a multitude of top scientific advisors and highly experienced teams to support Hillstream.
  • “OncoBay is a natural partner for us, complementing the oncological expertise of our team,” said Randy Milby, CEO of Hillstream BioPharma.

Engine Capital Sends Letter to Brenntag’s Supervisory Board of Directors Regarding the Need for a Timely Spin-off of the Specialties Business

Retrieved on: 
Tuesday, February 14, 2023
Professional Services, Finance, DNA, Organization, XETRA, Element, Jefferies, Specialization, Supervision, Acquisition, EBITDA, Supervisory board, Chemical substance, Citigroup, Culture, Letter, SOTP, Capital market, Growth, Share repurchase, Speciality chemicals, Member, IMCD, Fine chemical, Audit, Cryptocurrency, Car rental, Property management, Brenntag, Univar Solutions

Add a shareholder representative with relevant capital allocation, investing and valuation analysis experience to the Supervisory Board.

Key Points: 
  • Add a shareholder representative with relevant capital allocation, investing and valuation analysis experience to the Supervisory Board.
  • Separating Brenntag Specialties will allow the business to achieve its full potential as a standalone entity and help unlock long-term value for Brenntag stakeholders.
  • As a result, the best specialties salespeople want to work for specialties pure-play distributors, further compounding the advantages of that business model.
  • Therefore, we request a meeting with members of the Supervisory Board as soon as possible to discuss the matters and initiatives set forth in this letter.

Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb’s Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable

Retrieved on: 
Thursday, December 1, 2022
IMCD, COVID-19, Epitope, Ferroptosis, Heart, Charles, Bispecific monoclonal antibody, PD-1, Engineering, Antibody, IND, Safety, Acquisition, Partnership, Biotechnology, Therapy, Ion, Neoplasm, Toxicity, Tumor microenvironment, Protein, Half-life, KDA, Security (finance), Biology, Monoclonal antibody, CDR, H3, Cell death, Mining, Risk, Failure, PD-L1, Coronavirus, Organic acid, Iron, Animal, Complementarity, FDA, Algorithm, Palladium, Fine chemical, Vaccine, Pharmaceutical industry, Minotaur, Hillstream loach

BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”) today announced the development of proprietary targeted biologics, Knob Quatrabodies™ (HSB-1940) against PD-1. Hillstream signed separate collaboration agreements with a subsidiary of OmniAb, Inc. (Nasdaq: OABI) (“OmniAb”) and with Minotaur Therapeutics, Inc. (“Minotaur”) to advance Picobodies against novel, unreachable and undruggable epitopes in high-value validated targets starting with PD-1.

Key Points: 
  • Targeting PD-1 is a step toward enabling Hillstream to enter the rapidly growing Immuno-oncology (IO) therapeutics market with additional IO targets after PD-L1.
  • Alternative species, particularly camelids and bovines, provide a paradigm for antigen recognition through novel domains which form the antigen binding site.
  • However, for camelids, heavy chain antibodies bind antigen with only a single heavy chain variable region, in the absence of light chains.
  • At ~4-6 kDa, these are three times smaller than a camelid nanobody, and are the smallest known antibody fragment.

Hillstream BioPharma to Present at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

Retrieved on: 
Tuesday, November 22, 2022
IMCD, Ferroptosis, Conference, Initial public offering, IND, Biotechnology, Toxicity, Tumor microenvironment, Drug development, Reed Smith, Cell death, Iron, FDA, Pharmaceutical industry, Hillstream loach

Mr. Randy Milby, Founder and Chief Executive Officer of Hillstream BioPharma will present on Tuesday December 6th at 11:40 am ET.

Key Points: 
  • Mr. Randy Milby, Founder and Chief Executive Officer of Hillstream BioPharma will present on Tuesday December 6th at 11:40 am ET.
  • Mr. Milby will be available for one-on-one meetings and also for additional appointments with members of the investment community.
  • To access the live webcast and subsequent archived recordings for the presentation, please visit the Hillstream BioPharma website at: www.hillstreambio.com .
  • TheRHK Capital Disruptive Growth Conferenceis a two-day conference offering the exclusive opportunity to discover growth companies with disruptive technologies and business models focusing on solutions to unmet medical needs.

Proactive news headlines including Poseidon Nickel, Krakatoa Resources, Brookside Energy and Nova Minerals

Retrieved on: 
Monday, November 21, 2022
Poseidon, Well, TPD, 2010 Australian federal budget, Health, ADN, AOI, Black Swan Project, BSX, DUN, NED, Gold, Mineral, Research, KTA, Carbon, BFS, Nickel, HHI, REE, CSG, Great, OTC, Carnage, Lachlan Fold Belt, ASX, CPH, Case Western Reserve University, CWRU, Tower, DSF Refractories & Minerals Ltd, MRE, MSV, Whiteness Project, AVL, Copper, SHP, MGV, NVA, R, US, POS, OTCQB, BRU, PGE, IMCD, White, GTM, OTCQX, Proactivity, Sale, RC, Hydrogen, Tiwi, VMS, Rare-earth element, Oil, Renewable energy, Uranium, Mining, NSW

Click here

Key Points: 
  • Click here
    Nova Minerals Ltd (ASX:NVA, OTCQB:NVAAF) has received firm commitments for a placement to raise A$30 million (US$20 million) at A$0.70 per share.
  • Click here
    Talon Energy Ltd (ASX:TPD) welcomes the progress being made by partner TMK Energy Ltd at the Gurvantes XXXV CSG Project in the South Gobi Basin in Mongolia.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Hillstream’s New Anti-Cancer Mechanism Quatramer-based Ferroptosis Inducer, HSB-1216 Abstract Available for Viewing at EORTC-NCI-AACR Symposium

Retrieved on: 
Tuesday, October 18, 2022
Leukemia, Acute myeloid leukemia, IND, AML, Cytokine, Neoplasm, ENA, Biotechnology, Patient, Decitabine, LSCS, Rupture, Tumor microenvironment, Cell death, Toxicity, CEO, Prognosis, Iron, GLOBE, IMCD, Stem cell, Peptide, FDA, Poster, NCI, Ferroptosis, Pharmaceutical industry, Vaccine, Hillstream loach

Unfortunately, despite recent advances in the treatment, the prognosis is poor for almost all older adults and half of patients under age 60.

Key Points: 
  • Unfortunately, despite recent advances in the treatment, the prognosis is poor for almost all older adults and half of patients under age 60.
  • Leukemic stem cells (LSCs) represent a subset of the leukemic cell population contributing to leukemia relapse and are relatively refractory to conventional treatments.
  • HSB-1216 treatment resulted in growth inhibition and induction of cell death of multiple AML cell lines.
  • HSB-1216 is a novel and potent inducer of an emerging mechanism of cell death called ferroptosis.

Hillstream BioPharma, Inc. to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, October 6, 2022
Iron, IMCD, Tumor microenvironment, Biotechnology, Cell death, FDA, IND, Toxicity, Time, Ferroptosis, Risk management, Pharmaceutical industry

Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers.

Key Points: 
  • Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers.
  • Hillstreams most advanced candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors.
  • Hillstream intends to initiate IND discussions with the FDA in first half of 2023.
  • Hillstream uses Quatramer, our proprietary tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment with an extended duration of action and minimal off-target toxicity.